Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SML009
MIFTS: 57

Small Intestine Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Small Intestine Adenocarcinoma

About this section

MalaCards integrated aliases for Small Intestine Adenocarcinoma:

Name: Small Intestine Adenocarcinoma 12 15
Small Intestinal Adenocarcinoma 12 20 17
Adenocarcinoma of Small Intestine 12 70
Adenocarcinoma of the Small Bowel 20 58
Adenocarcinoma of the Small Instestine 20
Adenocarcinoma of the Small Intestine 58
Adenocarcinoma of Small Instestine 20
Adenocarcinoma of Small Bowel 20
Small Bowel Adenocarcinoma 20

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:4906
NCIt 50 C7888
SNOMED-CT 67 424440001
ICD10 via Orphanet 33 D01.4
UMLS via Orphanet 71 C0278803
Orphanet 58 ORPHA104075
UMLS 70 C0278803
Sources

Summaries for Small Intestine Adenocarcinoma

About this section
GARD : 20 Small intestine adenocarcinoma is one type of small bowel cancer, usually occurring in the duodenum or jejunum, that begins in the gland cells. The small intestine is part of the body's digestive syste m, which also includes the esophagus, stomach, and large intestine. The exact cause is still unknown, but it may be due to DNA changes in the small intestine adenocarcinoma cells. The symptoms of small bowel tumors are often vague. The most common symptoms are pain in the belly (which may be the first symptom), weight loss, weakness, fatigue and low red blood cell counts ( anemia ). The treatment and prognosis for small intestine cancer depends on its stage (t umor size and site) and the presence of metastases. For early stage cancer, surgery may be all that is needed. For more advanced cancer chemotherapy or radiation therapy may be required. Please visit the National Cancer Institute website for additional information: Small Intestine Cancer Treatment (PDQR)-Patient Version

MalaCards based summary : Small Intestine Adenocarcinoma, also known as small intestinal adenocarcinoma, is related to familial adenomatous polyposis 2 and appendix adenocarcinoma. An important gene associated with Small Intestine Adenocarcinoma is S100A4 (S100 Calcium Binding Protein A4), and among its related pathways/superpathways are Pathways in cancer and PKC-Theta Pathway. The drugs Fentanyl and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include small intestine, colon and lung, and related phenotypes are immune system and digestive/alimentary

Disease Ontology : 12 A small intestine carcinoma that derives from epithelial cells of glandular origin.

Sources

Related Diseases for Small Intestine Adenocarcinoma

About this section

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Small Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 familial adenomatous polyposis 2 30.3 MUC6 MLH1
2 appendix adenocarcinoma 30.2 KRAS HRAS
3 mucinous adenocarcinoma 29.9 MUC5AC MLH1 KRAS
4 in situ carcinoma 29.9 LCOR HRAS CTNNB1
5 jejunal adenocarcinoma 29.8 PMS2 MSH6 MLH1
6 hereditary nonpolyposis colon cancer 29.8 PMS2 MSH6 MSH2 MLH1
7 large intestine adenocarcinoma 29.8 KRAS HRAS CTNNB1
8 jejunal cancer 29.7 PMS2 MSH6 MSH2 MLH1
9 lynch syndrome i 29.6 PMS2 MSH6 MSH2 MLH1
10 adenocarcinoma 29.4 MSH6 MSH2 MLH1 KRAS HRAS CTNNB1
11 familial adenomatous polyposis 29.3 MSH6 MSH2 MLH1 KRAS HRAS CTNNB1
12 neurofibromatosis 28.9 PMS2 MSH6 MSH2 MLH1 KRAS HRAS
13 colorectal adenocarcinoma 28.8 PMS2 MSH6 MSH2 MLH1 KRAS HRAS
14 duodenum adenocarcinoma 28.8 PMS2 MUC6 MUC5AC MSH6 MSH2 MLH1
15 adenoma 28.8 MUC6 MUC5AC MSH6 MSH2 MLH1 KRAS
16 lynch syndrome 28.7 PMS2 MSH6 MSH2 MLH1 KRAS HRAS
17 li-fraumeni syndrome 28.6 PMS2 MSH6 MSH2 MLH1 KRAS HRAS
18 endometrial cancer 28.6 PMS2 MSH6 MSH2 MLH1 KRAS HRAS
19 duodenum cancer 28.2 PMS2 MUC6 MUC5AC MSH6 MSH2 MLH1
20 small intestine cancer 27.4 S100A14 PMS2 MUC6 MUC5AC MSH6 MSH2
21 intestinal obstruction 10.4
22 crohn's colitis 10.4
23 colorectal cancer 2 10.3 MSH2 MLH1
24 intracranial meningioma 10.3 MSH2 MLH1
25 silent pituitary adenoma 10.3 MSH6 MSH2
26 deficiency anemia 10.3
27 lower lip cancer 10.3 MSH2 MLH1
28 atypical polypoid adenomyoma 10.2 MLH1 CTNNB1
29 adenomyoma 10.2 MLH1 CTNNB1
30 cervical adenoma malignum 10.2 MUC6 MSH2
31 iron deficiency anemia 10.2
32 ileus 10.2
33 spindle cell intraocular melanoma 10.2 PMS2 MLH1
34 gastrointestinal carcinoma 10.1
35 anal fistula 10.1 MSH2 MLH1
36 renal pelvis transitional cell carcinoma 10.1 MSH6 MSH2 MLH1
37 hepatic flexure cancer 10.1 KRAS HRAS
38 intussusception 10.1
39 autosomal dominant non-syndromic intellectual disability 8 10.1 MSH6 MSH2 MLH1
40 trachea carcinoma in situ 10.1 KRAS HRAS
41 signet ring basal cell carcinoma 10.1 KRAS HRAS
42 cobblestone retinal degeneration 10.1 KRAS HRAS
43 keratoacanthoma 10.1 MSH2 MLH1 CTNNB1
44 immature teratoma of ovary 10.1 KRAS HRAS
45 breast-ovarian cancer, familial 1 10.1 MSH6 MSH2 MLH1
46 colorectal cancer, hereditary nonpolyposis, type 4 10.1 PMS2 MLH1
47 descending colon cancer 10.1 KRAS HRAS
48 ampulla of vater benign neoplasm 10.1 KRAS HRAS
49 biliary papillomatosis 10.1 MUC6 MUC5AC
50 alveolar soft part sarcoma 10.1 MSH2 MLH1 CTNNB1

Graphical network of the top 20 diseases related to Small Intestine Adenocarcinoma:



Diseases related to Small Intestine Adenocarcinoma
Sources

Symptoms & Phenotypes for Small Intestine Adenocarcinoma

About this section

MGI Mouse Phenotypes related to Small Intestine Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.85 CPS1 CTNNB1 KRAS MLH1 MSH2 MSH6
2 digestive/alimentary MP:0005381 9.8 CTNNB1 HRAS KRAS MLH1 MSH2 MUC5AC
3 mortality/aging MP:0010768 9.73 CPS1 CTNNB1 HRAS KRAS LCOR MLH1
4 neoplasm MP:0002006 9.23 CTNNB1 HRAS KRAS MLH1 MSH2 MSH6
Sources

Drugs & Therapeutics for Small Intestine Adenocarcinoma

About this section

Drugs for Small Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
3
Ondansetron Approved Phase 3 99614-02-5 4595
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
5
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
6
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
7
Fluorouracil Approved Phase 3 51-21-8 3385
8 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
9 Narcotics Phase 3
10 Anesthetics Phase 3
11 Anesthetics, Intravenous Phase 3
12 Anesthetics, General Phase 3
13 Analgesics, Opioid Phase 3
14 Analgesics Phase 3
15 Psychotropic Drugs Phase 3
16 Antiemetics Phase 3
17 Gastrointestinal Agents Phase 3
18 glucocorticoids Phase 3
19 Hormone Antagonists Phase 3
20 Antineoplastic Agents, Hormonal Phase 3
21 Anti-Inflammatory Agents Phase 3
22 Neurotransmitter Agents Phase 3
23 Antipsychotic Agents Phase 3
24 Anti-Anxiety Agents Phase 3
25 Dermatologic Agents Phase 3
26 Antimetabolites Phase 3
27
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
28
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
29
Floxuridine Approved Phase 2 50-91-9 5790
30
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
31
Melphalan Approved Phase 2 148-82-3 4053 460612
32
Hydroxyurea Approved Phase 2 127-07-1 3657
33
Lenograstim Approved, Investigational Phase 2 135968-09-1
34
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
35
Bevacizumab Approved, Investigational Phase 2 216974-75-3
36
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
37
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
38
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
39
leucovorin Approved Phase 2 58-05-9 6006
40
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
41
ramucirumab Approved, Investigational Phase 2 947687-13-0
42
Pembrolizumab Approved Phase 2 1374853-91-4
43
Acetaminophen Approved Phase 2 103-90-2 1983
44
Pancrelipase Approved, Investigational Phase 2 53608-75-6
45
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
Camptothecin Experimental Phase 2 7689-03-4
48
Lexatumumab Investigational Phase 2 845816-02-6
49
Molgramostim Investigational Phase 2 99283-10-0
50 Anti-Infective Agents Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
4 BALLAD BELGIUM: A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma Recruiting NCT04257461 Phase 3 Fluoropyrimidine;Oxaliplatin
5 PRODIGE 33 - BALLAD - Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma Not yet recruiting NCT02502370 Phase 3 observation alone;LV5FU2;FOLFOX
6 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
7 Pilot Study of Intraperitoneal (IP) Therapy With Cisplatin or Carboplatin and Floxuridine (FUdR) as Consolidation for Ovarian and Gastrointestinal Malignancies Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
8 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
9 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
10 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
11 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
12 A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
13 Phase II Study of Abraxane in CIMP-High Colorectal Adenocarcinomas and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
14 Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin
15 Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01202409 Phase 2 Panitumumab
16 A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
17 Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma Recruiting NCT04205968 Phase 2 Fluorouracil;Irinotecan;Irinotecan Hydrochloride;Leucovorin;Leucovorin Calcium;Paclitaxel
18 A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas Active, not recruiting NCT02949219 Phase 2
19 Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine Active, not recruiting NCT03000179 Phase 2 Avelumab
20 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
21 Pilot Study of Gemcitabine and IORT/EBRT in Locally Advanced Upper Gastrointestinal Malignancies Completed NCT00544193 Phase 1 gemcitabine hydrochloride
22 A Pharmacogenetic-Based Phase I Trial of Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
23 Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer. Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
24 Pilot Study of Oxaliplatin in Combination With Capecitabine in Adult Cancer Patients Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
25 A Phase I Dose-Escalating Study of Recombinant Human Interleukin-12 (NSC # 672423) Administered by Intraperitoneal Infusion in Refractory Advanced Stage Ovarian Cancer and Other Abdominal Carcinomatosis Completed NCT00003439 Phase 1
26 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1
27 A Phase I Clinical Trial To Assess The Safety And Efficacy Of Intraperitoneal PV701 Administrations In Patients With Advanced Or Recurrent Malignancy Largely Confined To The Peritoneal Cavity Completed NCT00055705 Phase 1
28 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
29 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
30 Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies Completed NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
31 Phase I Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis, Associated With Mullerian and Gastrointestinal Carcinomas Completed NCT00003046 Phase 1
32 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
33 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
34 A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System Completed NCT00010023 Phase 1 capecitabine;cisplatin
35 Visceral Lymphatic Mapping Project: A Pilot Study Completed NCT00489515
36 Improving Palliative Care for Patients With Cancer Completed NCT00253383
37 Phenotyping of Small Bowel Adenocarcinoma Completed NCT02976090

Search NIH Clinical Center for Small Intestine Adenocarcinoma

Sources

Genetic Tests for Small Intestine Adenocarcinoma

About this section
Sources

Anatomical Context for Small Intestine Adenocarcinoma

About this section

MalaCards organs/tissues related to Small Intestine Adenocarcinoma:

40
Small Intestine, Colon, Lung, Ovary, Appendix, Liver, Thyroid
Sources

Publications for Small Intestine Adenocarcinoma

About this section

Articles related to Small Intestine Adenocarcinoma:

(show top 50) (show all 117)
# Title Authors PMID Year
1
Neoplasia-Associated Wasting Diseases with Economic Relevance in the Sheep Industry. 61
33546178 2021
2
Small Intestinal Adenocarcinoma in a Patient With Celiac Disease. 61
33665060 2021
3
Tumor Microenvironmental Prognostic Risk in Primary Operable Small Intestinal Adenocarcinoma. 61
33443865 2021
4
Comment on Jun, S.Y.; et al. "Tumor Budding and Poorly Differentiated Clusters in Small Intestinal Adenocarcinoma" Cancers 2020, 12, 2199. 61
33076252 2020
5
Reply to Comment on "Jun, S.Y.; et al. Tumor Budding and Poorly Differentiated Clusters in Small Intestinal Adenocarcinoma" Cancers 2020, 12, 2199. 61
33076410 2020
6
Prognostic implication of SOX2 expression in small intestinal adenocarcinoma. 61
33103210 2020
7
Tumor Budding and Poorly Differentiated Clusters in Small Intestinal Adenocarcinoma. 61
32781596 2020
8
A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma. 61
32487033 2020
9
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs. 61
32267594 2020
10
[A rare case of cystadenoma in the small intestine]. 61
32306027 2020
11
Insurance status is related to overall survival in patients with small intestine adenocarcinoma: A population-based study. 61
31548047 2020
12
Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma. 61
31685233 2020
13
Loss of HES-1 Expression Predicts a Poor Prognosis for Small Intestinal Adenocarcinoma Patients. 61
32974155 2020
14
Prognostic Significance of Stromal and Intraepithelial Tumor-Infiltrating Lymphocytes in Small Intestinal Adenocarcinoma. 61
31576398 2020
15
Ileal Signet Ring Cell Carcinoma Masked by Crohn Disease. 61
33071669 2020
16
Detection of the Bacteroides fragilis toxin gene in sheep with and without small intestinal adenocarcinoma. 61
31378159 2019
17
Celiac disease: a comprehensive current review. 61
31331324 2019
18
Assessment of the external validity of the AJCC 8th staging system for small intestinal adenocarcinoma: a time to reconsider the role of tumor location? 61
31183191 2019
19
DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma. 61
30381262 2019
20
Retrospective study of survival time and prognostic factors for dogs with small intestinal adenocarcinoma treated by tumor excision with or without adjuvant chemotherapy. 61
30605388 2019
21
Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. 61
30375264 2018
22
[A Case of Intussusception in the Jejunum Due to Small Intestinal Adenocarcinoma]. 61
30237385 2018
23
Influence of marital status on small intestinal adenocarcinoma survival: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. 61
30532589 2018
24
Pancreatic non-functioning neuroendocrine tumor: a new entity genetically related to Lynch syndrome. 61
29184699 2017
25
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma? 61
28821192 2017
26
Metastatic intestinal adenocarcinoma to a lymph node involved by follicular lymphoma: The importance of looking beyond the apparent. 61
28476376 2017
27
Lynch syndrome-related small intestinal adenocarcinomas. 61
28206961 2017
28
Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas. 61
27169755 2016
29
[A Case of Ileocecal Intussusception Due to Small Intestinal Adenocarcinoma]. 61
28133155 2016
30
Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma. 61
26892442 2016
31
[A Case of Long-Term Survival in a Patient with Small Intestinal Adenocarcinoma with Peritoneal Dissemination]. 61
26809539 2016
32
Insulin-Like Growth Factor II mRNA-Binding Protein 3 (IMP3) as a Useful Immunohistochemical Marker for the Diagnosis of Adenocarcinoma of Small Intestine. 61
26855452 2015
33
[A Case of Small Bowel Cancer Treated with Laparoscopic Surgery]. 61
26805147 2015
34
Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma. 61
25710579 2015
35
[Four Cases of Primary Small Intestinal Cancer]. 61
26805145 2015
36
SMALL INTESTINAL ADENOCARCINOMA WITH CARCINOMATOSIS IN A SWIFT FOX (VULPES VELOX). 61
26352968 2015
37
Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. 61
25930983 2015
38
Lifestyle factors and small intestine adenocarcinoma risk: A systematic review and meta-analysis. 61
25736860 2015
39
Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine. 61
25759539 2015
40
Small bowel imaging in celiac disease. 61
25925931 2015
41
[A case of long-term survival of small intestinal adenocarcinoma treated by resection and chemotherapy]. 61
25731553 2014
42
Prognostic significance of CDX2 and mucin expression in small intestinal adenocarcinoma. 61
24603585 2014
43
Notch3 signaling is associated with MUC5AC expression and favorable prognosis in patients with small intestinal adenocarcinomas. 61
24810798 2014
44
Recovering a stuck capsule … and discovering a rare small-intestinal adenocarcinoma. 61
24679662 2014
45
[A case report of primary adenocarcinoma of the small intestine with peritoneal dissemination treated with multidisciplinary therapy]. 61
25129097 2014
46
S100A4 expression is a prognostic indicator in small intestine adenocarcinoma. 61
24062356 2014
47
Coexistence of granulomatous enteric inflammation and neoplasia in an adult sheep. 61
23456963 2013
48
Molecular alterations of EGFR in small intestinal adenocarcinoma. 61
23644682 2013
49
Epithelial-mesenchymal transition phenotype is associated with patient survival in small intestinal adenocarcinoma. 61
24018801 2013
50
Small intestinal adenocarcinoma: rarely considered, often missed? 61
23412393 2013
Sources

Variations for Small Intestine Adenocarcinoma

About this section

Cosmic variations for Small Intestine Adenocarcinoma:

9 (show top 50) (show all 63667)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88261999 ZRSR2 small intestine,duodenum,carcinoma,adenocarcinoma c.611G>A p.S204N 23:15815730-15815730 20
2 COSM149332692 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.1691C>T p.A564V 16:72958455-72958455 20
3 COSM149265665 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.8576C>T p.T2859M 16:72794106-72794106 20
4 COSM102022089 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.5834C>T p.T1945M 16:72794106-72794106 20
5 COSM87297052 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.1691C>T p.A564V 16:72958455-72958455 20
6 COSM102048731 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.-23-7490C>T p.? 16:72958455-72958455 20
7 COSM87273173 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.8576C>T p.T2859M 16:72794106-72794106 20
8 COSM147427236 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.742G>T p.D248Y 11:32428524-32428524 20
9 COSM149740983 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.742G>T p.D248Y 11:32428524-32428524 20
10 COSM91382445 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.35C>T p.P12L 11:32435311-32435311 20
11 COSM91384162 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.742G>T p.D248Y 11:32428524-32428524 20
12 COSM100782778 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.106G>T p.D36Y 11:32428524-32428524 20
13 COSM111540053 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.742G>T p.D248Y 11:32428524-32428524 20
14 COSM148594361 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.742G>T p.D248Y 11:32428524-32428524 20
15 COSM149739481 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.35C>T p.P12L 11:32435311-32435311 20
16 COSM148592624 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.35C>T p.P12L 11:32435311-32435311 20
17 COSM111538152 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.35C>T p.P12L 11:32435311-32435311 20
18 COSM113484181 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.35C>T p.P12L 11:32435311-32435311 20
19 COSM113485996 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.742G>T p.D248Y 11:32428524-32428524 20
20 COSM130519914 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.106G>T p.D36Y 11:32428524-32428524 20
21 COSM147425396 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.35C>T p.P12L 11:32435311-32435311 20
22 COSM123185138 UTP23 small intestine,duodenum,carcinoma,adenocarcinoma c.309C>T p.I103= 8:116849008-116849008 20
23 COSM127844360 UTP23 small intestine,duodenum,carcinoma,adenocarcinoma c.166C>T p.R56C 8:116849008-116849008 20
24 COSM102445723 U2AF1 small intestine,duodenum,carcinoma,adenocarcinoma c.473C>T p.S158L 21:43093133-43093133 20
25 COSM112018225 U2AF1 small intestine,duodenum,carcinoma,adenocarcinoma c.473C>T p.S158L 21:43093133-43093133 20
26 COSM99368626 U2AF1 small intestine,duodenum,carcinoma,adenocarcinoma c.692C>T p.S231L 21:43093133-43093133 20
27 COSM85193879 U2AF1 small intestine,duodenum,carcinoma,adenocarcinoma c.692C>T p.S231L 21:43093133-43093133 20
28 COSM150355656 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
29 COSM149802842 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
30 COSM151516785 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 20
31 COSM148988238 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3422C>A p.A1141E 16:2080318-2080318 20
32 COSM90410655 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 20
33 COSM150576440 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
34 COSM87029034 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
35 COSM101187420 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3275C>A p.A1092E 16:2080318-2080318 20
36 COSM151748199 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
37 COSM110110346 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3311C>A p.A1104E 16:2080318-2080318 20
38 COSM102619164 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
39 COSM101181610 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.563C>T p.P188L 16:2056705-2056705 20
40 COSM110104649 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.599C>T p.P200L 16:2056705-2056705 20
41 COSM87035637 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 20
42 COSM151751181 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3422C>A p.A1141E 16:2080318-2080318 20
43 COSM148982588 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
44 COSM90404630 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
45 COSM151371240 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 20
46 COSM136618407 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.743C>T p.P248L 16:2056705-2056705 20
47 COSM150320723 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3419C>A p.A1140E 16:2080318-2080318 20
48 COSM102625731 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3419C>A p.A1140E 16:2080318-2080318 20
49 COSM151374623 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 20
50 COSM149809484 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3419C>A p.A1140E 16:2080318-2080318 20

Copy number variations for Small Intestine Adenocarcinoma from CNVD:

7 (show all 22)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13776 1 1 39600000 Copy number LCK Small bowel adenocarcinoma
2 13777 1 1 39600000 Copy number MDS2 Small bowel adenocarcinoma
3 13778 1 1 39600000 Copy number PAX7 Small bowel adenocarcinoma
4 13779 1 1 39600000 Copy number PRDM16 Small bowel adenocarcinoma
5 13780 1 1 39600000 Copy number RPL22 Small bowel adenocarcinoma
6 13781 1 1 39600000 Copy number SDHB Small bowel adenocarcinoma
7 76578 13 32900000 93800000 Copy number LCP1 Small bowel adenocarcinoma
8 76579 13 32900000 93800000 Copy number LHFPL6 Small bowel adenocarcinoma
9 76580 13 32900000 93800000 Copy number RB1 Small bowel adenocarcinoma
10 106872 17 1 6800000 Copy number USP6 Small bowel adenocarcinoma
11 180663 4 10900000 191273063 Copy number CHIC2 Small bowel adenocarcinoma
12 180664 4 10900000 191273063 Copy number FBXW7 Small bowel adenocarcinoma
13 180665 4 10900000 191273063 Copy number FIP1L1 Small bowel adenocarcinoma
14 180666 4 10900000 191273063 Copy number IL2 Small bowel adenocarcinoma
15 180667 4 10900000 191273063 Copy number KIT Small bowel adenocarcinoma
16 180668 4 10900000 191273063 Copy number PDGFRA Small bowel adenocarcinoma
17 180669 4 10900000 191273063 Copy number PHOX2B Small bowel adenocarcinoma
18 180670 4 10900000 191273063 Copy number RAP1GDS1 Small bowel adenocarcinoma
19 244962 9 1 51800000 Copy number FANCG Small bowel adenocarcinoma
20 244963 9 1 51800000 Copy number JAK2 Small bowel adenocarcinoma
21 244964 9 1 51800000 Copy number MLLT3 Small bowel adenocarcinoma
22 244965 9 1 51800000 Copy number PAX5 Small bowel adenocarcinoma
Sources

Expression for Small Intestine Adenocarcinoma

About this section
Search GEO for disease gene expression data for Small Intestine Adenocarcinoma.
Sources

Pathways for Small Intestine Adenocarcinoma

About this section

Pathways related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 36
12.52 MSH6 MSH2 MLH1 KRAS HRAS CTNNB1
2
PKC-Theta Pathway 63
Show member pathways
 12.42 MSH6 MSH2 MLH1 KRAS HRAS
3
Immune response IL-23 signaling pathway 23
Show member pathways
 12.36 MSH2 KRAS HRAS CTNNB1
4
Endometrial cancer 36
Show member pathways
 12.32 MSH6 MSH2 MLH1 KRAS HRAS CTNNB1
5
CLEC7A (Dectin-1) signaling 65
Show member pathways
 12.19 MUC6 MUC5AC KRAS HRAS
6
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
11.93 MARCKS HRAS CTNNB1
7
Signaling pathways regulating pluripotency of stem cells 36
11.92 KRAS HRAS CTNNB1
8
Integrated Breast Cancer Pathway 1
11.89 MSH6 MSH2 KRAS CTNNB1
9
Direct p53 effectors 1
11.87 PMS2 MSH2 MLH1
10
G12-G13 in Cellular Signaling 63
11.82 KRAS HRAS CTNNB1
11
Thyroid hormone signaling pathway 36
11.81 KRAS HRAS CTNNB1
12
DNA Damage Response (only ATM dependent) 1
11.77 KRAS HRAS CTNNB1
13
Glioblastoma Multiforme 63
11.73 KRAS HRAS CTNNB1
14
Colorectal Cancer Metastasis 63
11.57 MSH6 MSH2 MLH1 KRAS CTNNB1
15
Mismatch repair 1 65 36
Show member pathways
 11.54 PMS2 MSH6 MSH2 MLH1
16
Platinum drug resistance 36
11.5 MSH6 MSH2 MLH1
17
Extracellular vesicle-mediated signaling in recipient cells 1
11.02 KRAS HRAS CTNNB1
18
CD209 (DC-SIGN) signaling 65
10.95 KRAS HRAS
19
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling 1
10.88 KRAS HRAS
21
p38MAPK events 65
10.61 KRAS HRAS
22
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 60
10.39 PMS2 MSH6 MSH2 MLH1
Sources

GO Terms for Small Intestine Adenocarcinoma

About this section

Cellular components related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex GO:0032389 9.16 PMS2 MLH1
2 MutSalpha complex GO:0032301 8.96 MSH6 MSH2
3 mismatch repair complex GO:0032300 8.92 PMS2 MSH6 MSH2 MLH1

Biological processes related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 DNA repair GO:0006281 9.88 PMS2 MSH6 MSH2 MLH1
2 negative regulation of neuron apoptotic process GO:0043524 9.77 MSH2 KRAS HRAS
3 liver development GO:0001889 9.71 KRAS HRAS CPS1
4 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.62 MUC6 MUC5AC KRAS HRAS
5 determination of adult lifespan GO:0008340 9.58 MSH6 MSH2
6 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.58 MSH6 MSH2 MLH1
7 epithelial tube branching involved in lung morphogenesis GO:0060441 9.57 KRAS CTNNB1
8 regulation of long-term neuronal synaptic plasticity GO:0048169 9.56 KRAS HRAS
9 negative regulation of DNA recombination GO:0045910 9.55 MSH6 MSH2
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.52 MSH2 MLH1
11 response to isolation stress GO:0035900 9.51 KRAS HRAS
12 embryonic axis specification GO:0000578 9.49 STIL CTNNB1
13 positive regulation of helicase activity GO:0051096 9.48 MSH6 MSH2
14 positive regulation of isotype switching to IgA isotypes GO:0048298 9.46 MSH2 MLH1
15 mismatch repair GO:0006298 9.46 PMS2 MSH6 MSH2 MLH1
16 maintenance of DNA repeat elements GO:0043570 9.43 MSH6 MSH2
17 isotype switching GO:0045190 9.43 MSH6 MSH2 MLH1
18 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.37 MSH2 MLH1
19 somatic recombination of immunoglobulin gene segments GO:0016447 9.13 MSH6 MSH2 MLH1
20 somatic hypermutation of immunoglobulin genes GO:0016446 8.92 PMS2 MSH6 MSH2 MLH1

Molecular functions related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.8 MSH6 MSH2 MLH1 CTNNB1
2 ATPase activity GO:0016887 9.73 PMS2 MSH6 MSH2 MLH1
3 single-stranded DNA binding GO:0003697 9.63 PMS2 MSH2 MLH1
4 four-way junction DNA binding GO:0000400 9.48 MSH6 MSH2
5 MutSalpha complex binding GO:0032407 9.4 PMS2 MLH1
6 MutLalpha complex binding GO:0032405 9.37 MSH6 MSH2
7 oxidized purine DNA binding GO:0032357 9.32 MSH6 MSH2
8 single guanine insertion binding GO:0032142 9.26 MSH6 MSH2
9 single thymine insertion binding GO:0032143 9.16 MSH6 MSH2
10 guanine/thymine mispair binding GO:0032137 9.13 MSH6 MSH2 MLH1
11 mismatched DNA binding GO:0030983 8.92 PMS2 MSH6 MSH2 MLH1
Sources

Sources for Small Intestine Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....